World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
77
Citations
40101
World Ranking
18239
National Ranking
9098

Margaret von Mehren publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Margaret von Mehren sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 298 publications — 16th percentile

16% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Margaret von Mehren D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Margaret von Mehren sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 77 D-Index — 10th percentile

10% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Margaret von Mehren is affiliated with the Fox Chase Cancer Center in the United States. Their research primarily focuses on medical studies related to oncology, with particular attention to gastrointestinal tumors and sarcomas.

Their work covers several main fields of study, including:

  • Medicine

Within medicine, von Mehren has contributed extensively to subfields such as:

  • Pulmonary and Respiratory Medicine
  • Gastroenterology
  • Oncology
  • Surgery
  • Cardiology and Cardiovascular Medicine

The main topics addressed in von Mehren's research include:

  • Gastrointestinal Tumor Research and Treatment
  • Sarcoma Diagnosis and Treatment
  • Gastric Cancer Management and Outcomes
  • Cardiac Tumors and Thrombi
  • Gastrointestinal Disorders and Treatments
  • Vascular Tumors and Angiosarcomas
  • Neurofibromatosis and Schwannoma Cases

Von Mehren has published numerous papers, with some recent and notable examples being:

  • Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology (2022), Journal of the National Comprehensive Cancer Network
  • Gastrointestinal stromal tumours (2021), Nature Reviews Disease Primers
  • Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial (2020), The Lancet Oncology
  • NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021 (2020), Journal of the National Comprehensive Cancer Network
  • Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial (2020), The Lancet Oncology

Frequent co-authors in von Mehren's publications include:

  • Suzanne George
  • Michael C. Heinrich
  • Robin L. Jones
  • Jonathan C. Trent
  • Sebastian Bauer

Publication venues where von Mehren's work has appeared commonly are:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Journal of the National Comprehensive Cancer Network
  • Cancer
  • Clinical Cancer Research

Best Publications

  • Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

    George Daniel Demetri;Margaret von Mehren;Charles D. Blanke;Annick Diane Van Den Abbeele

  • Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

    Michael C. Heinrich;Christopher L. Corless;George D. Demetri;Charles D. Blanke

  • Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

    Ronald P. DeMatteo;Karla V. Ballman;Cristina R. Antonescu;Robert G. Maki

  • Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

    George D Demetri;Peter Reichardt;Yoon-Koo Kang;Jean-Yves Blay

  • Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

    Charles D. Blanke;Cathryn Rankin;George D. Demetri;Christopher W. Ryan

  • Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT

    Charles D Blanke;George D Demetri;Margaret von Mehren;Michael C Heinrich

  • NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors

    George D. Demetri;Margaret Von Mehren;Cristina R. Antonescu;Ronald P. DeMatteo

  • NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

    George D. Demetri;Robert S. Benjamin;Charles D. Blanke;Jean Yves Blay

  • Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors

    Michael C. Heinrich;Christopher L. Corless;Charles D. Blanke;George D. Demetri

  • Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO

    Jean Yves Blay;Sylvie Bonvalot;Paolo Casali;Haesun Choi

  • Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial

    George D. Demetri;Margaret von Mehren;Robin L. Jones;Martee L. Hensley

  • Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.

    Michael C. Heinrich;Kouros Owzar;Christopher L. Corless;Donna Hollis

  • Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology

    Margaret von Mehren;R. Lor Randall;Robert S. Benjamin;Sarah Boles

  • Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules

    George D. Demetri;Sant P. Chawla;Margaret von Mehren;Paul Ritch

  • Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.

    Burton L. Eisenberg;Jonathan Harris;Charles D. Blanke;George D. Demetri

  • Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors

    George D. Demetri;Yanfeng Wang;Elisabeth Wehrle;Amy Racine

  • Phase I Pharmacokinetic and Biologic Correlative Study of Mapatumumab, a Fully Human Monoclonal Antibody With Agonist Activity to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor-1

    Anthony W. Tolcher;Monica Mita;Neal J. Meropol;Margaret von Mehren

  • Monoclonal antibody therapy for cancer.

    Margaret von Mehren;Gregory P. Adams;Louis M. Weiner

  • Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.

    Sosipatros A. Boikos;Alberto S. Pappo;J. Keith Killian;Michael P. LaQuaglia

  • Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial

    Christopher L. Corless;Karla V. Ballman;Cristina R. Antonescu;Violetta Kolesnikova

Frequent Co-Authors

George D. Demetri
George D. Demetri Dana-Farber Cancer Institute
Michael Heinrich
Michael Heinrich Oregon Health & Science University
Suzanne George
Suzanne George Harvard University
Robert G. Maki
Robert G. Maki University of Pennsylvania
Jean-Yves Blay
Jean-Yves Blay Claude Bernard University Lyon 1
Shreyaskumar Patel
Shreyaskumar Patel The University of Texas MD Anderson Cancer Center
Hans Gelderblom
Hans Gelderblom Leiden University Medical Center
Heikki Joensuu
Heikki Joensuu University of Helsinki
Christopher L. Corless
Christopher L. Corless Oregon Health & Science University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative online degrees and career pathways can broaden your opportunities in medicine and healthcare. For nurses seeking leadership or advanced clinical roles, pursuing affordable dnp programs might be an excellent option. These programs offer flexibility and can lead to top-tier positions in patient care or academics, often at a more reasonable cost.

If you want to start your nursing career quickly, lpn online programs allow students to enter the workforce faster while still learning essential clinical skills. Many find this a smart stepping stone to more advanced nursing roles later on.

Those interested in mental health can consider the shortest online pmhnp programs. These help registered nurses specialize in psychiatric and mental health, addressing a critical need in healthcare today.

Finally, for aspiring administrators, enrolling in a health care administration online degree prepares you for leadership in clinics, hospitals, or healthcare organizations. Online options are often more affordable and flexible, making them suitable for working professionals.

Best Scientists Citing Margaret von Mehren

Trending Scientists

Recently Published Articles